Document Detail


The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
MedLine Citation:
PMID:  18654064     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 2 diabetes mellitus and obesity share a pathogenic relationship, and both have rapidly increased in prevalence over the past decade. This review evaluates the effects of antidiabetes therapies on weight and glycemic control in the type 2 diabetes mellitus population. A PubMed search was conducted to identify randomized controlled trials that reported the weight effects of antidiabetes treatments. The search focused on the newer incretin-based therapies, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Antiobesity drugs and treatment options potentially available to patients with type 2 diabetes mellitus, including bariatric surgery, were also examined. Most of the established antidiabetes therapies (eg, sulfonylureas, thiazolidinediones) promote weight gain, thereby exacerbating insulin resistance and glucose intolerance. Dipeptidyl peptidase-4 inhibitors exhibit a weight-neutral profile, however, and GLP-1 receptor agonists (eg, exenatide, liraglutide) have achieved significant body weight reductions in spite of improved glycemic control, which is often accompanied by weight gain. Antiobesity drugs, such as orlistat and sibutramine, are effective weight-lowering agents in patients with type 2 diabetes mellitus, but safety and tolerability concerns may limit their use. Bariatric surgery in obese patients is associated with improved glycemic values and decreased mortality. Clinical evidence substantiating the weight-neutral effects of DPP-4 inhibitors and the weight-loss effects of GLP-1 agonists is promising, offering an expansion of therapeutic options for overweight and obese patients with type 2 diabetes mellitus. Evidence on the clinical utility of antiobesity drugs is more equivocal, and more data are needed to evaluate the safety and tolerability of these agents.
Authors:
F Xavier Pi-Sunyer
Related Documents :
16385384 - The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-...
17090794 - Incretin mimetics and dpp-iv inhibitors: new paradigms for the treatment of type 2 diab...
14678954 - Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
16492694 - Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric dis...
20556574 - A possible mechanism linking hyperglycemia and reduced high-density lipoprotein cholest...
21693744 - Risk of incident diabetes with intensive-dose compared with moderate-dose statin therap...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Postgraduate medicine     Volume:  120     ISSN:  1941-9260     ISO Abbreviation:  Postgrad Med     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-25     Completed Date:  2008-10-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401147     Medline TA:  Postgrad Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-17     Citation Subset:  AIM; IM    
Affiliation:
Obesity Research Center, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA. fxp1@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diabetes Mellitus, Type 2 / complications,  drug therapy*
Humans
Hypoglycemic Agents / pharmacology*,  therapeutic use
Obesity / etiology,  prevention & control*
Weight Loss / drug effects*
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Internal hernia after laparoscopic gastric bypass surgery: a case report and literature review.
Next Document:  Schizophrenia, obesity, and antipsychotic medications: what can we do?